Standard cell panel screen - 2D OncoSignature™

Identify sensitive and resistant cell lines
  • Pre-selected cancer cell lines (Horizon's library)
  • Single therapeutic drug screening or combination drug screening
  • Growth inhibition measure by ATP levels

Long-term cell panel screen – 2D OncoSignature™

Identify slow acting and epigenetic targets
  • 10-days assay format
  • Large panel of 248 cancer cell lines
  • Single or combination studies
  • Growth inhibition measured by ATP levels

Matrix combination screens

Find out the benefits of drug combination screening and how it helps improve cancer therapies.

Reveal the anti-proliferative signature of your drug

Use Horizon's screening services to identify sensitive or resistant cell lines to your drug 

'Horizon's OncoSignature HT screening platform for the prediction of anticancer drug sensitivity'

Set up a drug screen

Interview with Dr David Sorrell, Cell Panel Screening Manager, Horizon

Discussing the importance of efficacious screens to aiding patient stratification - 

'Power up your pipeline: maximizing single & combination screening for cancer’

App note: Compound screening in BRCA2 (-/-) cell lines

Isogenic cells are a powerful and relevant tool for therapeutic discovery and development.

View our results from:

  • Colony forming assay
  • Proliferation assay

Book a consultation with our screening experts

We're here to support informed decision making by providing:

  • Collaborative approach
  • Dedicated project manager
  • Regular updates & interim data
  • Detailed study report including raw data files and a free copy of our analysis workbench software